Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Millendo Therapeutics, Inc.
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Documented historical diagnosis of classic CAH due to 21-hydroxylase deficiency based on: Documented genetic mutation in the CYP21A2 enzyme consistent with a diagnosis of classic CAH, or historical documentation of elevated 17-hydroxyprogesterone
Biochemical marker of disease status of 17-hydroxyprogesterone ≥ 4 times the upper limit of normal
Chronic glucocorticoid replacement therapy for at least 6 consecutive months
Stable glucocorticoid and mineralocorticoid regimen for at least 1 month
You may not be if
Non-classic CAH
Other causes of adrenal insufficiency
Surgery within the previous 3 months prior to screening or planned surgery during study participation
History of active cancer requiring medical or surgical therapy within the past 6 months
